Market capitalization | $215.48m |
Enterprise Value | $69.93m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 51.04 |
P/S ratio (TTM) P/S ratio | 157.28 |
P/B ratio (TTM) P/B ratio | 0.93 |
Sales growth (TTM) Sales growth | -76.63% |
Turnover (TTM) Turnover | $1.37m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
5 Analysts have issued a Century Therapeutics Inc forecast:
5 Analysts have issued a Century Therapeutics Inc forecast:
Mar '24 |
+/-
%
|
||
Turnover | 1.37 1.37 |
77%
77%
|
|
Gross income | -9.60 -9.60 |
132%
132%
|
|
EBITDA | -113 -113 |
4%
4%
|
EBIT (operating result) EBIT | -124 -124 |
3%
3%
|
Net profit | -133 -133 |
7%
7%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It engages in harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.
Head office | United States |
CEO | Brent Pfeiffenberger |
Employees | 165 |
Founded | 2018 |
Website | www.centurytx.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.